Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Debt / NOTE 2.250% 4/0
-
Number of holders
-
34
-
Total principal
-
571M
-
Principal change
-
+7.48M
-
Total reported value, excl. options
-
$587M
-
Value change
-
+$11.5M
-
Number of buys
-
15
-
Number of sells
-
-13
-
Price
-
$1.03
Significant Holders of ASCENDIS PHARMA A/S - NOTE 2.250% 4/0 as of Q4 2023
33 filings reported holding 04351PAD3 - ASCENDIS PHARMA A/S - NOTE 2.250% 4/0 as of Q4 2023.
ASCENDIS PHARMA A/S - NOTE 2.250% 4/0 has 34 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $571M of principal
.
Largest 10 bondholders include WOLVERINE ASSET MANAGEMENT LLC ($140M of principal), BRAIDWELL LP ($127M of principal), FRANKLIN RESOURCES INC ($42.5M of principal), AVIVA PLC ($27M of principal), READYSTATE ASSET MANAGEMENT LP ($26M of principal), LINDEN ADVISORS LP ($24.4M of principal), D. E. Shaw & Co., Inc. ($22.8M of principal), ZAZOVE ASSOCIATES LLC ($18.3M of principal), Context Capital Management, LLC ($17.1M of principal), and Point72 Asset Management, L.P. ($17M of principal).
This table shows the top 34 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.